Xencor, Inc Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
Xencor, Inc (XNCR) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Amount of -$486.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherAdjustments · last filed 2026-02-25
- Xencor, Inc effective income tax rate reconciliation, other adjustments, amount for fiscal 2025 was -$486.00K, a 276.09% decline from fiscal 2024.
- Xencor, Inc effective income tax rate reconciliation, other adjustments, amount for fiscal 2024 was $276.00K, a 3.50% decline from fiscal 2023.
- Xencor, Inc effective income tax rate reconciliation, other adjustments, amount for fiscal 2023 was $286.00K.
- Xencor, Inc effective income tax rate reconciliation, other adjustments, amount for fiscal 2022 was -$74.00K, a 177.89% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$486.00K 10-K · filed 2026-02-25 | |
| 2024-12-31 | $276.00K 10-K · filed 2026-02-25 | |
| 2023-12-31 | $286.00K 10-K · filed 2026-02-25 | $417.00K 10-K · filed 2024-02-29 |
| 2022-12-31 | -$74.00K 10-K · filed 2025-02-27 | |
| 2021-12-31 | $95.00K 10-K/A · filed 2025-02-24 | |
| 2020-12-31 | $56.00K 10-K · filed 2023-02-27 | |
| 2019-12-31 | -$301.00K 10-K · filed 2022-02-24 | |
| 2018-12-31 | $414.00K 10-K · filed 2021-02-24 | |
| 2017-12-31 | $720.00K 10-K · filed 2020-02-25 | $262.00K 10-K · filed 2018-02-28 |
| 2016-12-31 | $1.01M 10-K · filed 2019-02-26 | $8.00K 10-K · filed 2017-03-01 |
| 2015-12-31 | $14.00K 10-K · filed 2018-02-28 | |
| 2014-12-31 | $2.00K 10-K · filed 2017-03-01 | |
| 2013-12-31 | $4.00K 10-K · filed 2016-03-08 | |
| 2012-12-31 | $12.00K 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |